Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1Phase 1/2 1

Status

Completed 4

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Other solid neoplasm 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × ARRY-334543 × Gastrointestinal × Clear all
NCT03130790 2022-02-15

Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)

ASLAN Pharmaceuticals

Phase 2/3 Completed
52 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03093870 2021-08-03

TreeTopp

ASLAN Pharmaceuticals

Phase 2/3 Completed
151 enrolled 18 charts
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms

NCT02609958 2018-05-29

ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

ASLAN Pharmaceuticals

Phase 2 Completed
32 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT00862524 2012-10-04

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Array BioPharma

Phase 1/2 Completed
20 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡